We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
+30.23%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$365M
(+24%)
Cap. Flow
+$51.2M
Cap. Flow
% of AUM
2.74%
Top 10 Holdings %
Top 10 Hldgs %
59.4%
Holding
57
New
5
Increased
14
Reduced
4
Closed
8
Top Buys
| 1 |
ETNB
89bio
ETNB
|
+$18.4M |
| 2 |
Structure Therapeutics
GPCR
|
+$18.2M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$13.8M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$12.8M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$12.1M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
+$36.6M |
| 2 |
Enliven Therapeutics
ELVN
|
+$14.3M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$8.71M |
| 4 |
Replimune Group
REPL
|
+$6.62M |
| 5 |
Prothena Corp
PRTA
|
+$6.17M |
Sector Composition
| 1 | Healthcare | 99.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$7.16B
| $192M | 10.25% |
6,495,392
+25,000
| +0.4% | +$757K |
|
|
HLVX
2
DELISTED
HilleVax
HLVX
| $157M | 8.39% |
9,781,472
| – | – |
|
3
NewAmsterdam Pharma
NAMS
$3.63B
| $136M | 7.25% |
12,131,705
| – | – |
|
4
Krystal Biotech
KRYS
$10.1B
| $123M | 6.56% |
988,460
| – | – |
|
5
BridgeBio Pharma
BBIO
$15.7B
| $110M | 5.88% |
2,725,949
| – | – |
|
6
Rhythm Pharmaceuticals
RYTM
$7.28B
| $109M | 5.83% |
2,371,304
| – | – |
|
7
Phathom Pharmaceuticals
PHAT
$875M
| $92.3M | 4.93% |
10,109,279
| – | – |
|
8
Vaxcyte
PCVX
$8.09B
| $73.1M | 3.91% |
1,164,405
| – | – |
|
|
VRNA
9
DELISTED
Verona Pharma
VRNA
| $59.9M | 3.2% |
3,014,349
| – | – |
|
|
ALPN
10
DELISTED
Alpine Immune Sciences Inc
ALPN
| $59.7M | 3.19% |
3,131,008
+145,251
| +5% | +$2.02M |
|
|
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
| $53M | 2.83% |
885,165
+271,122
| +44% | +$13.8M |
|
12
Rocket Pharmaceuticals
RCKT
$372M
| $45.6M | 2.44% |
1,523,013
+120,000
| +9% | +$2.65M |
|
13
Disc Medicine
IRON
$2.81B
| $45.3M | 2.42% |
785,000
+130,000
| +20% | +$6.66M |
|
|
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
| $44.4M | 2.37% |
3,622,294
+383,435
| +12% | +$3.49M |
|
15
Tarsus Pharmaceuticals
TARS
$2.52B
| $36.2M | 1.94% |
1,787,527
| – | – |
|
|
16
Edgewise Therapeutics
EWTX
$4.11B
| $29.2M | 1.56% |
2,667,203
+1,818,181
| +214% | +$12.8M |
|
17
Revolution Medicines
RVMD
$38.1B
| $28.6M | 1.53% |
997,455
| – | – |
|
18
AN2 Therapeutics
ANTX
$168M
| $28.5M | 1.52% |
1,388,889
| – | – |
|
19
Arcutis Biotherapeutics
ARQT
$3.47B
| $28.3M | 1.51% |
8,764,232
+80,000
| +0.9% | +$217K |
|
|
JBIO
20
Jade Biosciences
JBIO
$1.25B
| $27.3M | 1.46% |
34,425
| – | – |
|
|
AUTL
21
Autolus Therapeutics
AUTL
$389M
| $24.1M | 1.29% |
3,746,857
| – | – |
|
22
MacroGenics
MGNX
$262M
| $23.1M | 1.24% |
2,401,704
+598,500
| +33% | +$4.14M |
|
23
Acadia Pharmaceuticals
ACAD
$4.39B
| $22.9M | 1.22% |
730,917
+100,020
| +16% | +$2.39M |
|
|
ETNB
24
DELISTED
89bio
ETNB
| $22.3M | 1.19% |
+2,000,000
| New | +$18.4M |
|
|
MRUS
25
DELISTED
Merus
MRUS
| $20.5M | 1.1% |
746,479
| – | – |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG